Medically reviewed by Isabel Casimiro, MD, PhD Hypoparathyroidism is a rare condition characterized by the diminished ...

Drawing from personal experience, Patty Keating advocates for greater awareness, improved diagnosis, and treatment among ...

SINGAPORE, Feb. 21, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the registration of YORVIPATH ® (palopegteriparatide) by the Therapeutic Goods ...

Expert Rev Endocrinol Metab. 2012;7(3):255-257. The future of hormone replacement therapy in hypoparathyroidism can be viewed with optimism, even if we are left with several unanswered questions ...

Septerna (SEPN) announced its decision to discontinue the Phase 1 single- and multiple-ascending dose clinical trial of SEP-786 in healthy ...

Septerna Inc. has announced its decision to discontinue a healthy volunteer phase I trial of SEP-786, an oral small-molecule agonist of the parathyroid hormone 1 receptor being developed for the ...

Hypoparathyroidism is a rare condition characterized by inadequate levels of parathyroid hormone (PTH) or resistance to PTH, leading to a wide range of health complications and reduced quality of ...

Septerna discontinues phase 1 clinical trial of SEP-786; plans to advance next-generation oral small molecule PTH1R agonist: South San Francisco, California Friday, February 21, 2 ...

This can cause a wide range of problems. You’ll need an accurate diagnosis because hypoparathyroidism symptoms can be similar to those in a lot of other diseases and conditions. It’s important ...

Septerna Inc.’s stock plunged as much as 68% throughout the day Feb. 18 on news that the company was stopping a phase I trial of SEP-786 in healthy volunteers following two severe events of elevated ...

Specialised Therapeutics welcomes the registration of YORVIPATH by the Therapeutic Goods Administration, “for the treatment of chronic ...